Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients

Archives of Internal Medicine

Volumn 160, Issue 9, 2000, Pages 1277-1283

  Elliott, William J ^a,c   Weir, David R ^b   Black, Henry R ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CLINICAL PROTOCOL; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE SIMULATION; HEALTH CARE COST; HUMAN; HYPERTENSION; LIFE EXPECTANCY; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0034621505     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.9.1277     Document Type: Article

References (52)

1. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 1997; 157:2413-2446.
2. Stewart IMDG. Relation of reduction in pressure to first myocardial intarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-865.
3. Cruickshank JM, Thorpe JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1:581-584.
4. Farnett L, Mulrow CD, Linn WD, Lucey CR, Tuley MR. The J-curve phenomenon and the treatment of hypertension: is there a point beyond which pressure reduction is dangerous? JAMA. 1991;265:489-495.
5. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
6. Jacobson HR, Striker GE. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. Am J Kidney Dis. 1995;25:153-156.
7. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1998;21(suppl):S23-S31.
8. Hansson L, Zanchetti A, Julius S. et al, on behalf of the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755-1762.
9. Turner R, Holman R, Stratton I, et al, for the United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:707-713.
10. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-186.
11. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
12. Levy D, Larson MG, Ramchandran SV, Kannel WB, Kalon KL. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
13. Perry HM, Miller JP, Fornoff JR, et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension. 1995;25:587-594.
14. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the MRFIT Research Group. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1996;16:434-444.
15. Rose G. Epidemiology. In Marshall AJ, Barritt DW, eds. The Hypertensive Patient. Kent, England: Pitman Medical Publishers; 1980:1-21.
16. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-1218.
17. Kostis JB, Davis BR, Cutler J, et al, for the SHEP Cooperative Research Group, Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition in diabetic nephropathy. N Engl J Med. 1993;323:1456-1462.
19. Giatras I, Lau J, Levey AS, for the Angiotensin Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Meta-analysis of the effectiveness of ACE-inhibitors in preventing the progression of renal disease. Ann Intern Med. 1997;127:337-345.
20. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer J, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
21. Lightwood JM, Glantz SA. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. Circulation. 1997;96:1089-1096.
22. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121: 951-957.
23. American Heart Association. 1999 Heart and Stroke Facts, Statistical Update. Dallas, Tex: American Heart Association; 1999.
24. Department of Health and Human Services. Health Care Financing Research Report: End Stage Renal Disease, 1991. Baltimore, Md: Health Care Financing Administration: 1991.
25. Weinstein MC, Seigel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276: 1253-1258.
26. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
27. Kittner SJ, White LR, Losonczy KG, Wolf PA, Hebel JR. Black-white differences in stroke incidence in a national sample: the contribution of hypertension and diabetes mellitus. JAMA. 1990;264:1267-1270.
28. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22:312-318.
29. CDC Diabetes Cost-effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757-1763.
30. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1990;121:293-298.
31. American Diabetes Association's Diabetes 1997 Vital Statistics. Alexandria, Va: American Diabetes Association; 1997.
32. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin dependent diabetes mellitus: a population-based study in Rochester, MN. Ann Intern Med. 1989;111:788-796.
33. Jorgensen HS, Nakayama H, Raaschou HO, Olsen TS. Acute stroke: prognosis and a prediction of the effect of medical treatment on outcome and healthcare utilization: The Copenhagen Stroke Study. Neurology. 1997;49:1335-1342.
34. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
35. Dennis MS, Burns JP, Sandercock PAG, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
36. McGovern PG, Folsom AR, Sprafka JM, et al. Trends in survival of hospitalized myocardial infarction patients between 1970 and 1985: the Minnesota Heart Survey. Circulation. 1992;85:172-179.
37. National Center for Health Statistics. Vital Statistics of the United States, 1992, Volume II: Mortality: Part A. Hyattsville, Md: US Dept of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention; 1995.
38. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol. 1988;128:389-401.
39. Ford ES, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes: findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol. 1991;133:1220-1230.
40. Panzram G. Mortality and survival in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia. 1987;30:123-131.
41. Hilleman DE, Mohiuddin SM, Lucas BD Jr, Stading JA, Stoysich AM, Ryschon K. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther. 1994;16:88-102.
42. Drugs for hypertension. Med Lett Drugs Ther. 1995;37:45-50.
43. Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens. 1998;11:618-629.
44. Raikou M, Gray A, Briggs A, et al, for the United Kingdom Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: USPDS 40. BMJ. 1998;317:720-726.
45. Huse DM, Oster G, Killen AR, Lacey MJ, Colditz GA. The economic costs of non-insulin-dependent diabetes mellitus. JAMA. 1989;262:2708-2713.
46. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990;263:407-413.
47. Rodby RA, Firth LM, Lewis EJ, for the Collaborative Study Group. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care. 1996; 19:1051-1061.
48. Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risks, and cumulative disability. N Engl J Med. 1998;339:481-482.
49. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation: Agency for Health Care Policy and Research. JAMA. 1998;278:1759-1766.
50. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared to streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.
51. Perreault S, Hamilton VH, Lavoie F, Grover S. Treating hyperlipidemia for the primary prevention of coronary disease: are higher dosages of lovastatin cost-effective? Arch Intern Med. 1998;158:375-381.
52. Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease: Scandinavian Simvastatin Survival Study Group. N Engl J Med. 1997;336:332-336.